



Sheet 01 of 05

Form PTO-1449 Modified		Docket No. WARF-0003	Serial No. 09/801,485
List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Applicant Dickerson and Helfand	
		Filing Date March 8, 2001	Group 1649
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
JS	AA	Angiolillo et al., "A Role for the Interferon-Inducible Protein 10 in Inhibition of Angiogenesis by Interleukin-12", <i>Ann NY Acad. Sci.</i> 1996 795:158-167	
	AB	Angiolillo et al., "Human Interferon-inducible Protein 10 Is a Potent Inhibitor of Angiogenesis In Vivo", <i>J. Exp. Med.</i> 1995 182:155-162	
	AC	Arap et al., "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model", <i>Science</i> 1998 279:377-380	
	AD	Arenberg et al., "Interferon- γ -inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases", <i>J. Exp. Med.</i> 1996 184:981-992	
	AE	Atkins et al., "Phase I Evaluation of Intravenous Recombinant Human Interleukin 12 in Patients with Advanced Malignancies ¹ ", <i>Clin. Cancer Res.</i> 1997 3:409-417	
	AF	Auerbach W. and Auerbach R., "Angiogenesis Inhibition: A Review", <i>Pharmac. Ther.</i> 1994 63:265-311	
	AG	Brooks et al., "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels", <i>Cell</i> 1994 79:1157-1164	
	AH	Brunda et al., "Antitumor and Antimetastatic Activity of Interleukin 12 against Murine Tumors", <i>J. Exp. Med.</i> 1993 178:1223-1230	
AI	Chan et al., "Induction of Interferon γ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers", <i>J. Exp. Med.</i> 1991 173:869-879		
EXAMINER 		DATE CONSIDERED 7/10/03	




Sheet 02 of 05

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. WARF-0003	Serial No. 09/801,485
		Applicant Dickerson and Helfand	
		Filing Date March 8, 2001	Group 1647
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
38	AJ	Coughlin et al., "The Effect of Interleukin 12 Desensitization on the Antitumor Efficacy of Recombinant Interleukin 12 ¹ ", <i>Cancer Res.</i> 1997 57:2460-2467	
	AK	Dias et al., "Multiple Molecular and Cellular Changes Associated with Tumour Stasis and Regression During IL-12 Therapy of a Murine Breast Cancer Model", <i>Int. J. Cancer</i> 1998 75:151-157	
	AL	Dias et al., "IL-12 Regulates VEGF and MMPs in a Murine Breast Cancer Model", <i>Int. J. Cancer</i> 1998 78:361-365	
	AM	Folkman J., "What Is the Evidence That Tumors Are Angiogenesis Dependent?", <i>J. Natl Cancer Inst.</i> 1990 82:4-6	
	AN	Folkman J., "Angiogenesis in cancer, vascular, rheumatoid and other disease", <i>Nature Med.</i> 1995 1:27-31	
	AO	Gasparini G., "Antiangiogenic drugs as a novel anticancer therapeutic strategy Which are the more promising agents? What are the clinical developments and indications?", <i>Crit. Rev. Onc. Hematol.</i> 1997 26:147-162	
	AP	Handel-Fernandez et al., "Down-Regulation of IL-12, Not a Shift from a T Helper-1 to a T Helper-2 Phenotype, Is Responsible for Impaired IFN- γ Production in Mammary Tumor-Bearing Mice", <i>J. Immunol.</i> 1997 158:280-286	
	AQ	Kobayashi et al., "Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), A Cytokine with Multiple Biologic Effects on Human Lymphocytes", <i>J. Exp. Med.</i> 1989 170:827-845	
41	AR	Koivunen et al., "Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins", <i>Biotechnology</i> 1995 13:265-270	
EXAMINER <i>gde</i>		DATE CONSIDERED <i>7/30/05</i>	



Sheet 03 of 05

Form PTO-1449 Modified		Docket No. WARF-0003	Serial No. 09/801,485
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Dickerson and Helfand	
		Filing Date March 8, 2001	Group 1647
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AS	Leonard et al., "Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12-Associated Toxicity and Interferon- γ Production", <i>Blood</i> 1997 90:2541-2548	
	AT	Lieberman et al., "Natural Killer Cell Stimulatory Factor (NKSF) Augments Natural Killer Cell and Antibody-Dependent Tumorcidal Response against Colon Carcinoma Cell Lines", <i>J. Surg. Res.</i> 1991 50:410-415	
	AU	Liotta et al., "Cancer Metastasis and Angiogenesis: An Imbalance of Positive and Negative Regulation", <i>Cell</i> 1991 64:327-336	
	AV	Lode et al., "Synergy between an antiangiogenic integrin α_v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases", <i>Proc. Natl Acad. Sci. USA</i> 1999 96:1591-1596	
	AW	Luster A.D. and Leder P., "IP-10, a -C-X-C- Chemokine, Elicits a Potent Thymus-dependent Antitumor Response In Vivo", <i>J. Exp. Med.</i> 1993 178:1057-1065	
	AX	Majewski et al., "Interleukin-12 Inhibits Angiogenesis Induced by Human Tumor Cell Lines In Vivo", <i>J. Invest. Dermatol.</i> 1996 106:1114-1118	
	AY	Nastala et al., "Recombinant IL-12 Administration Induces Tumor Regression in Association with IFN- γ Production ¹ ", <i>J. Immunol.</i> 1994 153:1697-1706	
	AZ	Robertson et al., "Immunological Effects of Interleukin 12 Administered by Bolus Intravenous Injection to Patients with Cancer ¹ ", <i>Clin. Cancer Res.</i> 1999 5:9-16	
	BA	Ruoslahti E., "The Walter Hervert Lecture - Control of cell motility and tumour invasion by extracellular matrix interactions" <i>Br. J. Cancer</i> 1992 66:239-242	
EXAMINER		DATE CONSIDERED 7/30/03	



Form PTO-1449 Modified		Docket No. WARF-0003	Serial No. 09/801,485
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Dickerson and Helfand	
		Filing Date March 8, 2001	Group 1647
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
85 ↓	BB	Sgadari et al., "Mig, the Monokine Induced By Interferon- γ , Promotes Tumor Necrosis In Vivo", <i>Blood</i> 1997 89:2635-2643	
	BC	Sgadari et al., "Inhibition of Angiogenesis by Interleukin-12 Is mediated by the Interferon-Inducible Protein 10", <i>Blood</i> 1996 87:3877-3882	
	BD	Soiffer et al., "Interleukin-12 Augments Cytolytic Activity of Peripheral Blood Lymphocytes From Patients With Hematologic and Solid Malignancies", <i>Blood</i> 1993 82:2790-2796	
	BE	Taub et al., "Recombinant Human Interferon-inducible Protein 10 Is a Chemoattractant for Human Monocytes and T Lymphocytes and Promotes T Cell Adhesion to Endothelial Cells", <i>J. Exp. Med.</i> 1993 177:1809-1814	
	BF	Voest et al., "Inhibition of Angiogenesis In Vivo by Interleukin 12", <i>J. Natl Cancer Inst.</i> 1995 87:581-586	
	BG	Watanabe et al., "Animal Model - Regulation of Local Host-Mediated Anti-Tumor Mechanisms by Cytokines - Direct and Indirect Effects on Leukocyte Recruitment and Angiogenesis", <i>Am. J. Pathol.</i> 1997 150:1869-1880	
	BH	Wigginton et al., "Interleukin 12 Primes Macrophages for Nitric Oxide Production in Vivo and Restores Depressed Nitric Oxide Production by Macrophages from Tumor-bearing Mice: Implications for the Antitumor Activity of Interleukin 12 and/or Interleukin 2", <i>Cancer Res.</i> 1996 56:1131-1136	
↓	BI	Zou et al., "Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN- γ production by anti-tumor T cells", <i>Intl Immunol.</i> 1995 7:1135-1145	
EXAMINER <i>gsc</i>		DATE CONSIDERED <i>7/30/03</i>	

